<DOC>
	<DOCNO>NCT00311090</DOCNO>
	<brief_summary>The three purpose study follow : - To compare 6-month treatment safety effectiveness idrabiotaparinux ( SSR126517 ) idraparinux ( SR34006 ) , take account new event deep venous thrombosis ( DVT ) pulmonary embolism ( PE ) , bleed risk ; - To compare activity idrabiotaparinux idraparinux directly blood 6-month treatment ; - To check ability avidin ( SSR29261 ) reverse blood thin activity idrabiotaparinux end 6-month treatment period .</brief_summary>
	<brief_title>Bioequipotency Study Idrabiotaparinux Idraparinux Patients With Deep Venous Thrombosis Lower Limbs</brief_title>
	<detailed_description>The study consist 6-month treatment period follow observational period 3 6 month month 9 visit phone/contact visit month 12 . All participant complete 6-month treatment period re-randomized either idrabiotaparinux/idraparinux bioequipotency sub-study avidin neutralize effect sub-study .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>SANORG 34006</mesh_term>
	<mesh_term>Biotin</mesh_term>
	<criteria>Confirmed acute symptomatic DVT low limb Severe concomitant disease ( e.g . renal failure , hepatic failure , uncontrolled hypertension ) Active bleed high risk bleeding . Pregnancy childbearing potential without proper contraceptive measure . Breastfeeding Known allergy idraparinux , SSR126517E , egg protein Indication prolong anticoagulation reason DVT low limbs Symptomatic pulmonary embolism ( PE ) Life expectancy &lt; 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Deep Venous Thrombosis</keyword>
</DOC>